article thumbnail

FDA Finalizes Its Informed Consent Guidance for IRBs, Clinical Investigators and Sponsors

Hall Render

Food and Drug Administration (“FDA”) finalized “ Informed Consent: Guidance for IRBs, Clinical Investigators, and Sponsors ” (“Final Guidance”), following the FDA’s earlier issuance of draft guidance on the subject in July 2014. On August 15, 2023, the U.S. study sponsor, regulatory agencies, etc.)

article thumbnail

QMS 101: Pharmaceutical Quality Management System

Dot Compliance

It focuses on specific persons and processes involved in the production of goods and stops them from straying from quality standards like FDA 21 CFR Part 11, ISO and ICH Q10. Prior to ISO 9001:2015 , the standard for Quality Management Systems (QMS) was ISO 9001:2005. For cGMP compliance, the FDA audits authorized drug manufacturers.

FDA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Ultimate Guide to ISO 9001

Dot Compliance

Prior to ISO 9001:2015, the standard for Quality Management Systems (QMS) was ISO 9001:2005. The United States Food and Drug Administration (FDA) has the authority to enforce compliance with the Code of Federal Regulations , which has significant consequences if disregarded. ISO 9001 with Dot Compliance.

article thumbnail

3 Lessons Learned from Pandemic-Era Clinical Development Regulatory Practices

HIT Consultant

Ronan Brown, SVP and Head of Integrated Global Compliance, IQVIA. Food and Drug Administration (FDA), along with greater flexibility around mandates on alternatives to traditional clinical information. These approaches have combined to help accelerate FDA review and study commencement timelines to as low as 30 days.

article thumbnail

How the Medical Industry Can Help Combat the Current Coronavirus Crisis

Exeed Regulatory Compliance

FDA Guidance on EUA, Jan 2017 *Notes: Section 564 as in the Food, Drug and Cosmetic (FD&C Act); PAHPRA refers to the Pandemic and All-Hazards Preparedness Reauthorization Act of 2015 One area of current concern is the lack of diagnostic testing capability in the US to rapidly detect and confirm new cases.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – May And June

SQA

The rules of RDC 786/2023 correspond to a normative update, which replaces RDC 302/2005. Although this Toolkit provides PCPC’s current thinking on MoCRA, companies should be mindful that MoCRA represents meaningful new authorities that FDA has yet to interpret and apply. cosmetic regulatory framework.

FDA 40
article thumbnail

Unpacking Averages: Assessing the Racial Composition of Drug Clinical Trial Subjects

Health Law Advisor

The United States Food and Drug Administration (FDA) for many years has been trying to increase the participation of minorities in clinical trials to help ensure that regulated products are tested and labeled in an appropriate cross-section of Americans. National Library of Medicine, with support from FDA.

FDA 52